Top member reports
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
##Summary of Results Jan2025
stale
SNT-5505 (Myelofibrosis)
Phase 1/2a - Part 1 - Monotherapy SNT-5505 (Reported 12July2023)
Patient Population: Unresponsive or ineligible to JAK inhibitor drugs - life expectancy approx. 1 year.
Length: 6 months
Phase 1/2a - Part 2a - Combination SNT-5505 (200mg BID) + Ruxolitinib (Reported 10Dec2024)
Patient Population: 16 individuals with I2 or HR myelofibrosis (MF), symptomatic, stable RUX (ruxolitinib) 8 weeks.
Length: 12 months
Next Data: March 2025 - 12month
- Based of the images above, 5 at most could reach12months
- 7 patients of 16 have dropped out as of Dec 2024.
SNT-5505 (Myelodysplastic Syndromes)
- Preclinical Data (Doubled response rate)
- 2 upcoming studies - Aus phase 1c/2 and German 1/b2
- Grant Announcement for Phase 1/b2 high risk MDS and CMML.
- Not listed on Clinical trials.gov / Data anticipated H2 2025
SNT-4728 (IRDB and Parkinsons)
- Clinical Trial Registry
- Data anticipated H2 2025
Skin Scarring
- Phase 1C results
- Longer study planned - Pending protocol